ArticleScientific reports2025
Hypoxia suppressed the Siglec-5 signaling in TAMs via modulating the balance of SHP2/SYK activation in hepatocellular carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A bibliometric analysis of resistance to PD-1/PD-L1 inhibitors.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo investigate the effects of Siglec-5 on hepatocellular carcinoma and the mechanism of action. The interactions and expression changes between Siglec-5 and Siglec-14 not only affect immune cell function, but may also influence tumor progression. A deeper understanding of the mechanisms regulating their balance could provide new insights and strategies for hepatocellular carcinoma treatment.
methodsA cell co-culture model was established. Western blotting was used to detect protein expression in different groups. The CCK-8 assay was employed to observe the proliferation of HepG2 hepatocellular carcinoma cells, and the Transwell assay was used to examine their migration. Tumorigenic capacity of HepG2 cells detected by subcutaneous transplantation tumor assay in nude mice.
resultsOverexpression of Siglec-5 under hypoxic conditions resulted in increased levels of SHP2 and arginase-1 proteins and decreased levels of P-SYK, IL-1β, and TNFα proteins. Addition of SHP2 inhibitor under hypoxic conditions or Siglec-5 overexpression resulted in increased expression of P-SYK and NOX4 proteins and decreased levels of arginase-1. When Siglec-5 expression was inhibited under hypoxic conditions, the levels of P-SHP2 and arginase-1 were decreased, whereas the levels of P-SYK, IL-1β, and TNFα were increased. The expression of P-SYK, NOX4, IL-1β, and TNFα was decreased, whereas the levels of arginase-1 were increased after the use of SYK inhibitors under hypoxic conditions that inhibited Siglec-5 expression. The proliferation, migration and tumorigenicity of HepG2 cells were increased when Siglec-5 was overexpressed under hypoxic conditions, while the proliferation, migration and tumorigenicity of HepG2 cells were decreased when Siglec-5 was inhibited under hypoxic conditions.
conclusionHypoxia suppressed the Siglec-5 signaling in TAMs via modulating the balance of SHP2/SYK activation in hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.